AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; public-private sector testing response in general and specific to Influenza A (H5) avian flu, monkeypox and oropouche; H.R. 2377/S. 1000, Saving Access to Laboratory Services Act; H.R. 8702/S. 4532, Improving Seniors Timely Access to Care Act; and H.R. 2369, the Verifying Accurate Leading-edge IVCT Development Act (VALID Act) of 2023.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
| MARY LEE WATTS | — |
Medicare/Medicaid MMM
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); H.R. 2377/S. 1000, Saving Access to Laboratory Services Act; H.R. 8702/S. 4532, Improving Seniors Timely Access to Care Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
| MARY LEE WATTS | — |
Health Issues HCR
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule, test coding and pricing, coverage, and payment, and implementation of the Protecting Access to Medicare Act (P.L. 113-93); FDA and CMS policies related to diagnostics and laboratory regulation; price transparency for clinical laboratory services; H.R. 2377/S. 1000, Saving Access to Laboratory Services Act; H.R. 8818, Improving Seniors Timely Access to Care Act; H.R. 2369, the Verifying Accurate Leading-edge IVCT Development Act (VALID Act) of 2023; S. 3548.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
| MARY LEE WATTS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.